GALT vs. DSGN, PRLD, MACK, GBIO, OGI, RIGL, GTHX, ZVRA, FHTX, and IMMP
Should you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Design Therapeutics (DSGN), Prelude Therapeutics (PRLD), Merrimack Pharmaceuticals (MACK), Generation Bio (GBIO), Organigram (OGI), Rigel Pharmaceuticals (RIGL), G1 Therapeutics (GTHX), Zevra Therapeutics (ZVRA), Foghorn Therapeutics (FHTX), and Immutep (IMMP). These companies are all part of the "pharmaceutical preparations" industry.
Galectin Therapeutics (NASDAQ:GALT) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings.
Galectin Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.
Galectin Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500.
In the previous week, Galectin Therapeutics had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for Galectin Therapeutics and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 1.46 beat Galectin Therapeutics' score of 0.89 indicating that Design Therapeutics is being referred to more favorably in the news media.
Galectin Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 229.34%. Design Therapeutics has a consensus target price of $5.50, indicating a potential upside of 47.85%. Given Galectin Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Galectin Therapeutics is more favorable than Design Therapeutics.
Galectin Therapeutics' return on equity of 0.00% beat Design Therapeutics' return on equity.
Galectin Therapeutics received 336 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 60.31% of users gave Galectin Therapeutics an outperform vote while only 32.14% of users gave Design Therapeutics an outperform vote.
11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 52.7% of Galectin Therapeutics shares are owned by insiders. Comparatively, 27.8% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Galectin Therapeutics beats Design Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Galectin Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galectin Therapeutics Competitors List
Related Companies and Tools
